SOURCE: BioCentury Publications, Inc.

BioCentury Publications, Inc.

September 14, 2014 12:00 ET

BioCentury & BayHelix to Convene China Healthcare Summit in Shanghai This November

"THE BRIDGE TO INNOVATION" Will Probe the Crucial Next Steps to Creating a Modern Healthcare Ecosystem in China

REDWOOD CITY, CA and SHANGHAI, CHINA--(Marketwired - Sep 14, 2014) - BioCentury and BayHelix, in collaboration with McKinsey & Company, will convene "The Bridge to Innovation" China Healthcare Summit on November 12 and 13 at the Grand Hyatt Shanghai.

The Bridge to Innovation, the first BioCentury Summit in China, will bring together thought leaders and decision makers to identify the necessary next steps to building a modern healthcare system in China on a foundation of scientific, business and policy innovation.

The VIP dialogue will be driven by more than 100 influencers from Chinese and international biopharma companies, and the academic, policy and investment communities.

"The Bridge to Innovation will explore the common interests of the leading domestic pharmas, MNCs, policy makers and investors in building a modern healthcare system for patients in China," said David Flores, President & CEO of BioCentury. "We hope our collaboration with BayHelix and McKinsey & Company establishes a strategic forum for a continuing dialogue among these key stakeholders in China."

"China has made major progress in building an impressive infrastructure and an ecosystem conducive to innovation in life science," said Dr. Kewen Jin, Chairman of BayHelix. "We are very glad to work with BioCentury to organize The Bridge to Innovation conference, to bring together key opinion leaders and stakeholders to examine the challenges we face, to share the success stories and lessons learned, and to identify further steps to support healthcare innovation in China."

The importance of this first BioCentury Summit in China is demonstrated by its collaborators. Insights Partner McKinsey & Company is joined by Charter Sponsors Eddingpharm; Fountain Medical Development; Johnson & Johnson; KGI Securities; Kleiner Perkins Caufield & Byers China; Sidley & Austin; Takeda Pharmaceutical Company; and WuXi AppTec.

They are joined by Supporting Organizations SINO-PhIRDA, the China Pharmaceutical Industry Research & Development Association; RDPAC, the R&D-based Pharmaceutical Association Committee; the Lychee Group, the premier life sciences event partner in China; and the ChinaBio® Group, the leading China-based life science partnering and investment firm.

Attendance will be limited to assure intimate dialogue and networking by the participating VIPs. To take advantage of the early-bird registration discount, contact Tom Carey from BioCentury at tcarey@biocentury.com or Jon Liong from the Lychee Group at jon.liong@lycheegroup.com.

The Bridge to Innovation will commence on Wednesday, November 12, with release of an exclusive report from McKinsey & Company on the challenges for transforming biopharma business models as China's healthcare system evolves over the next decade.

The preliminary program features a series of "Town Hall" plenary sessions where conference attendees will participate in identifying:

  • Common Ground: Where China pharmas and MNCs share interests in modernizing the nation's healthcare ecosystem.
  • Mind the Gap: How new commercial models can sustain pharma P&Ls and build a bridge to innovation in China.
  • Benchmarks: Ways to measure progress as China develops a modern healthcare ecosystem.

Other top sessions are expected to include:

  • A Report Card on Healthcare Reform in China: What was accomplished for patients in the past 5 years, and what additional reforms are needed in the next 5 years?
  • Hallmarks of a Modern Healthcare Ecosystem: An international policy discussion led by BioCentury Washington Editor Steve Usdin, the host of BioCentury This Week television.
  • Access Strategies for the Next 5 Years: Case studies of cross-border commercial collaborations aiming to expand access to therapeutics in China.
  •  Deal-Making Strategies for the Next 5 Years: Case studies of cross-border R&D collaborations that are providing China pharmas with a bridge to innovation.
  • Financing Companies for the Next 5 Years: How investors are financing commercial efforts and pipeline portfolios from bases in China, Taiwan and Hong Kong.

The Bridge to Innovation also will host the annual BayHelix Awards for accomplishment by Chinese innovators in R&D, deal making and commercial operations.

The Organizing Committee for The Bridge to Innovation includes key thought leaders from both inside and outside China:

  • Organizing Committee Chair: Dr. Steve Yang, EVP & COO, WuXi AppTec
  • Dr. Kewen Jin, CEO, Symap Medical, and Chairman, BayHelix
  • Franck Le Deu, Partner and Head of Greater China Healthcare Practice, McKinsey & Company
  • Dr. Jimmy Zhang, VP, Transactions, Johnson & Johnson Innovation, and Immediate Past Chairman, BayHelix
  • Dr. Karen Bernstein, Chairman & Editor-in-Chief, BioCentury
  • David Flores, President & CEO, BioCentury
  • Joshua Berlin, Executive Director, New Ventures, BioCentury
  • Steve Usdin, Washington Editor, BioCentury
  • Dr. Debra Yu, Managing Director, Labrador Advisors
  • Jon Liong, Managing Partner, Lychee Group

To register to participate, see the latest agenda and speaker announcements, and learn about sponsorship opportunities please visit, http://www.biocentury.com/conferences/chinasummit/dates.

About BioCentury
The first BioCentury Summit in China builds on BioCentury's 15 years of leadership in initiating and building BioEquity Europe as the primary venue for regional leaders to address strategic challenges facing the European biopharma ecosystem. BioCentury also has been pleased to Co-Host the BIO Asia International Convention in Japan for the past 11 years. And this year, BioCentury has marked 21 years of supporting biotechnology on Wall Street with its two annual U.S. investor conferences in New York: Future Leaders in the Biotech Industry and NewsMakers in the Biotech Industry.

Since 1993, BioCentury Publications, Inc. has provided essential biopharma industry intelligence to a global audience of biotech and pharmaceutical executives, investors, regulators, public policy makers and the scientific community. This audience has benefited from BioCentury's deep knowledge, data-driven analysis, independent perspective and trustworthy content available through the company's publications, data products and collaborative industry conferences in the U.S., Europe and Asia.

BioCentury's titles include the flagship BioCentury®; its SciBX: Science-Business eXchange™ translational science partnership with Nature Publishing Group; and its BioCentury Extra™ mobile daily newspaper. These timely journals are backed by BCIQ™, an online business intelligence resource. BioCentury also produces its BioCentury This Week healthcare public affairs television program in partnership with the Gannett-owned WUSA9 CBS affiliate in Washington, D.C. The program is aired in Washington each Sunday, on selected Public Broadcasting System member stations and distributed globally online at www.biocenturytv.com.

For more information, visit www.biocentury.com and www.biocenturytv.com.

About BayHelix
BayHelix Group is a non-profit, invitation-only organization of business leaders of Chinese heritage whose mission is to foster the growth of the life sciences and healthcare industry. Founded in 2001, BayHelix has grown to over 500 members throughout the U.S., Canada, and Greater China. The membership base covers most of the world's top pharmaceutical and biopharmaceutical companies, as well as many leading services and investment firms. Over one third of the members are senior executives, over 80% have PhDs in the life sciences, and nearly half have MBAs from the leading business schools in the U.S.

For more information, visit http://bayhelix.org/